TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06125691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2138
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Quadrivalent Vaccine for younger adults
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Quadrivalent Vaccine for older adults
Description: Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
Study: NCT04745598

Intervention type: BEHAVIORAL
Intervention: Plaque-disclosing group
Description: - Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth

Intervention type: BEHAVIORAL
Intervention: Intra-oral camera group
Description: - An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
Study: NCT05556200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR2 Tyrosine Kinase Inhibitor
Description: Apatinib 250 mg, po, qd
Study: NCT05722626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: 2 ml of platelet rich plasma intraarticular injection twice in one week interval

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: NaCl 0.9%
Study: NCT05397509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive leaf tea
Description: 250 mL of Olive leaf tea and a high-glycemic breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 250 mL of placebo tea and a high-glycemic breakfast
Study: NCT05503485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Existential group treatment
Description: The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive telephone calls
Description: The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself.
Study: NCT05093894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Microlyte will be cut into strips and placed on the subcutaneous space
Study: NCT05450133

Intervention type: OTHER
Intervention: ASDAS-ESR
Description: The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).

Intervention type: OTHER
Intervention: ASDAS-CRP
Description: The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).

Intervention type: OTHER
Intervention: ASDAS-CRP
Description: The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).

Intervention type: OTHER
Intervention: MASES
Description: It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.

Intervention type: OTHER
Intervention: MASES
Description: It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
Study: NCT05862675

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA sequencing of blood samples
Description: Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
Study: NCT05563467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
Study: NCT04598646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio-oncology Rehabilitation (CORE)
Description: Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support
Description: Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
Study: NCT05275790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal device
Description: Battery powered non-invasive neurostimulation device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
Study: NCT06401590

Intervention type: DIAGNOSTIC_TEST
Intervention: FROZEN SENTINEL LYMPH NODE BIOPSY
Description: FROZEN SENTINEL LYMPH NODE BIOPSY
Study: NCT06028763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control
Description: Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture of ankle's cartilage lesion under arthroscopic control
Description: Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
Study: NCT05072002

Intervention type: OTHER
Intervention: no intervention / observational study
Description: no intervention / observational study
Study: NCT05851157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study: NCT06111729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabitAware group
Description: A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
Study: NCT05751915

Intervention type: DEVICE
Intervention: CardioFlux
Description: CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.

Intervention type: DEVICE
Intervention: CardioFlux
Description: CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.

Intervention type: DEVICE
Intervention: CardioFlux
Description: CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
Study: NCT05178563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPT+PDT
Description: The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IPT+Placebo
Description: IPT+Placebo
Study: NCT04669561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
Study: NCT06203925

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (oral fluid HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (oral fluid HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (blood-based HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (blood-based HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
Study: NCT05407311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-BBN
Description: 64Cu-SAR-BBN
Study: NCT05784025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlterG
Description: Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
Study: NCT06551233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
Study: NCT05225779

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 12- derivation Electrocardiography
Description: 6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 12- derivation Electrocardiography
Description: 6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
Study: NCT05332821

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
Study: NCT05881525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-N201 cells
Description: T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT05170282

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
Study: NCT06550765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Magnesium Metal Clips
Description: The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Study: NCT06501326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
Study: NCT05734079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A written hand out containing all information required for bowel preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care + Video call
Description: Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care + Video call + Educational video film
Description: Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
Study: NCT05326477

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral weight loss treatment
Description: The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
Study: NCT04785781

Intervention type: OTHER
Group type: OTHER
Intervention: without masks
Description: apply a bicycle ergometer test protocol to individuals without a mask

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)
Description: apply a bicycle ergometer test protocol to individuals with a surgical mask

Intervention type: OTHER
Group type: OTHER
Intervention: FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)
Description: apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
Study: NCT06283615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D2 injection
Study: NCT06501326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
Study: NCT05569382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: 1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Study: NCT04926259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-T807
Description: Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.